Research Paper

LncRNA-PVT1 indicates a poor prognosis and promotes angiogenesis via activating the HNF1B/EMT axis in glioma

Yongyan Bi1,2, Jie Ji3, Youxin Zhou1,∗

1. Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2. Department of Neurosurgery, Minhang Hospital, Fudan University, Minhang, Shanghai, China
3. Department of Rehabilitation Medicine, Minhang Hospital, Fudan University, Minhang, Shanghai, China

∗ Corresponding author: You-Xin Zhou. zhouyouxin@suda.edu.cn. Department of Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 899 Pinghai Street, Suzhou, Jiangsu, 215006, China

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2021.03.09; Accepted: 2021.07.12; Published: 2021.07.25

Abstract

Recent studies identified that long non-coding RNAs (lncRNAs) exhibited critical roles in tumor migration and invasion. However, the roles of lncRNAs in glioma remain unclear. The aim of this study was to uncover the underlying mechanisms of glioma progression and provide potential therapeutic targets for its treatment in clinic. Our microarray study showed that lncRNA-PVT1 was significantly upregulated in glioma tissues and played an important role in cell proliferation, migration, invasion and angiogenesis. Our data showed that the expression of lncRNA-PVT1 was increased obviously and associated with advanced tumor stage, metastasis, invasion ability, and poor prognosis in glioma patients. Up-regulation of lncRNA-PVT1 was observed to promote glioma cells proliferation, and invasion abilities in vitro as well as tumor growth in vivo by regulating miR-1207-3p expression. Online software (TargetScan, miRDB and miR TarBase) were used to predict the regulating mechanisms of lncRNA-PVT1, miR-1207-3p and HNF1B, which were validated by dual-luciferase reporter gene system. In vivo tumor-bearing mice models were established to validate the cellular results. Therefore, we suggested that lncRNA-PVT1/miR-1207-3p/HNF1B axis might play critical roles in glioma progression, indicating that lncRNA-PVT1/miR-1207-3p/HNF1B signaling axis may serve as novel molecular targets for glioma prevention and treatment.

Key words: lncRNA-PVT1, HNF1B, miR-1207-3p, glioma, EMT

Introduction

Human glioma that is derived from the neural ectoderm is the most common type of intracranial neoplasm, accounting for more than 50% [1]. Although therapeutic techniques, such as surgery, radiotherapy, and chemotherapy for glioma have achieved great strides, the median survival of glioma patients is only 9-12 months [2-3]. The poor prognosis and high recurrence rate of glioma is largely due to the abundant blood flow, rapid growth, susceptibility of invasion to surrounding normal brain tissues and resistance to radiotherapy and chemotherapy [4]. The tumorigenesis of glioma is biologically complex, involving a series of pathophysiological changes, and expression changes of many genes and signaling pathways [5]. Thus far, there is no definite conclusion about the underlying molecular mechanisms that mediate the tumorigenesis of brain glioma. Therefore, it is necessary to uncover the pathogenesis of glioma and develop effective diagnostic and therapeutic targets.

Long non-coding RNAs (lncRNAs) belong to ncRNA with a transcription length of more than 200 nt (nucleotides) and lack of protein coding functions [6]. Recently, accumulated evidence showed that lncRNAs play crucial roles in cellular functions, such as cell proliferation, apoptosis, differentiation,
metastasis, drug resistance [7-8]. Plasmacytoma variant translocation 1 (Inc-PVT1) is a lncRNA that has been found to serve an oncogenic role in a variety of malignant tumors [9]. Recent evidence further indicates that IncRNA-PVT1 exhibits aberrant expression in nonsmall-cell lung carcinoma [10], cervical carcinoma [11], colorectal carcinoma [12], and gastric carcinoma [13]. Located at 8q24, IncRNA-PVT1 has been identified as a candidate oncogene and highly expressed in multiple human neoplasms, which exerts regulatory functions in biological processes, such as proliferation, apoptosis, mobility, and invasion [14]. Moreover, IncRNA-PVT1 expression is significantly linked to patient survival in those with breast carcinoma, IncRNA-PVT1 has been shown to directly bind and stabilize the KLF5 proteins in breast cancer [15]. EZH2 forms a molecular complex with IncRNA-PVT1 to function as a repressive driver of p15 and p16 in gastric cancer [16]. IncRNA-PVT1 is also transcriptionally activated by FOXM1 in gastric cancer [17]. Furthermore, IncRNA-PVT1 induces radioresistance by influencing cell apoptosis and DNA repair in NPC [18]. Furthermore, the specific role of IncRNA IncRNA-PVT1 in the pathogenesis of glioma has become a viewpoint, as there were quite a few studies on the roles of IncRNA-PVT1 in glioma [19-20]. However, the underlying IncRNA-miRNA-mRNA regulatory networks involved with IncRNA-PVT1 in glioma are currently lacking.

MicroRNA has been frequently implicated in various cellular processes, including cell proliferation and apoptosis [21-23]. Emerging evidences revealed that miR-30 family was related with tumor development. For example, Zhao et al. showed that miR-30-5p functioned as a tumor suppressor by regulating Wnt/β-catenin-BCL9 axis [24]. Han et al. revealed that there is a feedback loop between miR-30a/c-5p and DNMT1 in the area of ovarian cancer cells resistance to cisplatin [25]. Gao et al. found that miR-30c-5p reduced invasion and EMT processes of gastric cancer via targeting MTA1 [26]. Some previous researches have indicated that miR-1207-3p was significantly upregulated, which might be potential cancer oncogene in different types of cancers, such as prostate cancer [27], gastric cancer [28], pancreatic cancer [29], and colorectal cancer [30]. Besides, miR-1207-3p has been found to exhibit a low expression and inhibit cell proliferation, suppress tumor growth, and block angiogenesis in medulloblastoma [31]. Nevertheless, the regulatory function of IncRNA-PVT1/miR-1207-3p axis in glioma cells needs to be further explored.

Herein, the purpose of the present study was to investigate the explicit role of IncRNA-PVT1 in the pathogenesis of glioma as well as the potential mechanism of IncRNA-PVT1/ miR-1207-3p/HNF1B axis in glioma. In the present study, we found that IncRNA-PVT1 was upregulated in glioma, and it predicted poor survival in patients. We delved into the IncRNA-miRNA-mRNA networks by co-expressing IncRNA and mRNA with altered miRNA. Bioinformatics analysis was used to predict possible pathways in which these networks might be involved.

Materials and Methods

Tissue samples collection

In our current study, glioma patient tissues and matched adjacent-tumor controls were obtained from the Department of Neurosurgery at Minhang Hospital of Fudan University, between May 2015 and December 2019. The collected tissues were immediately snap-frozen in liquid nitrogen and stored at -80°C before using. All the patients read and signed the informed consent forms and this study was approved by the Research Ethic Committee of the Fudan of University. Before surgery, none of the patients had received chemotherapy or radiation therapy.

Cell culture and transfection

Human glioma cell lines U87, SHG-44, U251, H4, human umbilical vein endothelia cells (HUVEC), human embryonic kidney 293T (HEK293T) cell line and normal cells (HEB) were purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences (Shanghai, China). Human microglia (HM, ATCC® CRL-3304™) was purchased from the American Type Culture Collection (Manassas, VA). Glioma cells were cultivated in DMEM containing 10% fetal bovine serum (FBS; Sigma-Aldrich, St.Louis, MO, USA) in an incubator with constant temperature containing 5% CO2 at 37°C. Glioma cells were transduced with lentiviral vector suppressing IncRNA-PVT1 (sh-IncRNA-PVT1), miR-1207-3p mimics, miR-1207-3p inhibitors and corresponding negative controls. All synthesis (sh-IncRNA-PVT1, miR-1207-3p mimics, miR-1207-3p inhibitors) are done by Shanghai IBSBIO. Cells were transfected with shRNA or miRNA via Lipofectamine 3000 reagents (Invitrogen, USA).

RNA extraction and quantitative real-time PCR

Total RNA was extracted from these included Glioma cells using TRIzol reagent based on the manufacturer’s instructions [32]. The cDNA was synthesized using Reverse Transcription Kit (Toyobo, Japan). qPCR assay was conducted using SYBR Green Real-time PCR Mix (Toyobo, Japan) and determined
in triplicate. The primer sequence of lncRNA-PVT1:
5’-GGGGAATAACGCTGGTGGA-3’, 5’-CCCATGG
ACATCCAAGCTGT-3’. Data were normalized to
GAPDH expression. The relative expression of target
genes were analyzed by the 2−ΔΔCt method. The PCR
program was set as follows: 50˚C for 2 min firstly,
followed by 95˚C for 10 min, and 38 cycles of 95˚C for
15 s and 60˚C for 1 min. U6 and GAPDH were served
as internal reference.

**Microarray analysis**

Total RNA was extracted from 3 paired glioma
tissues. Tissue samples preparation and microarray
hybridization were performed according to the
instructions. The raw data and array images were
extracted with Agilent Feature Extraction (version11,
Agilent, USA) software. Subsequent data processing
was done using the GeneSpring GX v12.0 (Agilent).
The microarray was provided by KangChen
(Shanghai, China). The threshold cutoff was a fold
change ≥2.0 and a P value ≤0.05 for downregulated
and upregulated lncRNAs.

**Western blot assay**

Total proteins from cells were extracted using
RIPA lysis buffer (Thermo Fisher, USA) and protein
concentrations were measured with BCA protein
assay (Pierce, IL, USA). Totally 45 µg of each protein
was separated through 15% SDS-PAGE gels and
transferred onto PVDF membranes according to the
instructions (Millipore, USA). After blocking with 5%
skimmed milk, the membranes were treated with
primary antibodies at 4˚C overnight. Then the
responding secondary antibody was used for 1h at
room temperature. Protein bands were visualized by
ECL (Thermo Fisher, USA). Soluble proteins were
analyzed by immunoblotting with anti-HNF1B
(07-2192; Sigma-Aldrich), anti-foxm1 (SAB3300002;
Thermo Scientific), anti-Vimentin (ab8069; Abcam),
anti-N-Cadherin (ab18203; Abcam), anti-p-ERK (mAb
#4370), anti-ERK (mAb #4695), anti-p65 (mAb #8242),
anti-ZEB1 (mAb #3396; Cell signaling Technology)
and anti-GAPDH (G8795; Sigma).

**Immunohistochemistry staining and scoring**

The experimental methods are based on
previous study. Specifically, staining intensity was
scored manually by two independent experienced
pathologists. For evaluation of IHC staining, a
semiquantitative scoring criterion was used, in which
both staining intensity and positive areas were
recorded. Obtained as the intensity of HNF1B positive
staining (negative =0, weak =1, moderate =2, or strong
=3 scores) and the proportion of immunopositive cells
of interest (<10% =1, 10%-50% =2, >50% and <80% =3,
>80% =4 scores), was calculated. In the case of
heterogeneous staining, we determined the percent-
age of different staining intensities individually in
each area and calculated the total sum (3). The
following primary antibodies were used: anti-HNF1B
(1:200 dilutions, Cell Signaling, Boston, USA).

**Cell proliferation assay**

The cell proliferation viability was assessed by
MTT assay (IBSBIO, China). Cells were seeded on
96-well plates in triplicates at the density of 1000-2000
cells/100 ml. Thereafter, 20 µl of MTT solution was
added and incubated at 37˚C for 5 h. The reaction
liquid was abandoned, then 200 µl of DMSO was
added. Finally, the optical density 470 (OD 470)
absorbance values were obtained in triplicate and
replicated 6 times.

**Cell cytoplasm/nucleus fraction isolation**

To prepare cytoplasmic and nuclear extracts
from glioma cells, NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Thermo Scientific, Waltham,
MA, USA) was used. RT-qPCR was employed to
analyze the levels of nuclear control transcript,
cytoplasmic control transcript and lncRNA-PVT1.

**Transwell assay**

Cell invasion ability was carried out by
Transwell invasion assay. Briefly, transfected cells
were seeded into 24-well upper chamber (Corning,
CA USA) pre-coated with Matrigel (Sigma, MO,
USA). The lower chamber was filled with DMEM
medium containing 10% FBS. After culturing for 24 h,
the invade cells were stained with 0.1% crystal violet
(SIGMA) for 10 min. The number of invaded cells was
counted under a light microscope (Nikon, Japan).

**Luciferase reporter assay**

lncRNA-PVT1 and HNF1B 3’UTR Wt and
mutant DNAs were amplified by PCR, then
separately inserted into pmiR-GLO vector (Promega)
to construct a Wt and Mut type of lncRNA-PVT1 and
HNF1B plasmids. Cells were transfected with Wt or
Mut reporter plasmid and miR-1207-3p mimics by
lipofectamine 3000 reagent (Invitrogen). After 48 h of
transfection, the luciferase activity was measured by
Dual-luciferase reporter assay system (Promega, CA,
USA).

**Tumor xenograft implantation in nude mice**

All BALB/c nude mice were purchased from
Shanghai Laboratory Animal Center (Shanghai, 
China). Before the experiments, the mice were
acclimatized to the new environment for one week.
Mice were randomized into different groups with
approximately equivalent numbers before tumor cell
inoculation. To determine the effects of IncRNA-PVT1
on tumor formation in vivo, glioma cells stably transfected with sh-lncRNA-PVT1 or sh-NC (2.0×10^6 cells/site) were injected subcutaneously into 4-6 weeks old female mice. The developing tumors were observed during the following 7 weeks, after which the mice were sacrificed. The weights of each tumor were also documented. Tumor volume was calculated as V = length × (width^2)/2. The protocol was approved by the Institutional Animal Care and Use Committee of Fudan University.

**Gene Set Enrichment Analysis (GSEA)**

GSEA (http://software.broadinstitute.org/gsea/ msigdb/index.jsp) software programs were used to analyze The Cancer Genome Atlas (TCGA) dataset. To interpret the function of regulated genes, GSEA (version 2.2.0) was performed using the 50 cancer hallmark gene sets and a gene log2-fold change. To identify the pathways that are correlated with lncRNA-PVT1 expression in tumor samples, we performed a similar GSEA for each cancer type in TCGA dataset. In this analysis, GSEA was performed on the ranked list based on the Spearman’s correlation coefficient with LncRNA-PVT1 expression.

**Statistical analysis**

In the present study, all of the statistical analysis was employed using SPSS 17.0 software package (SPSS Inc. Chicago, USA), GraphPad Prism 8.0 software (GraphPad, USA), and Microsoft office 2019 EXCEL (USA). p < 0.05 was considered statistically significant. Pearson χ^2 or Fisher’s exact test was performed to find out the associations between the indicators expression and clinicopathological parameters in our included glioma patients. Linear regression analysis was explored to analyze the correlation of lncRNA-PVT1 with other indicators. Student’s t-test (two-tailed) and Wilcoxon or Welch’s T-test were used to compare the significance differences of the paired and unpaired continuous variables between groups, presented as mean ± standard deviation (s.d.) or median (quartile).

**Results**

**Microarray analysis demonstrates significant alterations in lncRNA expression patterns in human glioma**

Differentially expressed lncRNAs (fold change ≥ 1.5 and p < 0.05) were observed in Figure 1A, there are 327 lncRNAs exhibited high expression levels and 559 lncRNAs exhibited low expression levels. Among the dysregulated lncRNA transcripts, the mostly upregulated lncRNAs were lncRNA-PVT1 and Inc-004831, of which lncRNA-PVT1 was the highest (log2FC = 4.32). In an attempt to further explore the function of lncRNA-PVT1 in a lncRNA-dependent manner, we first focused on 3 microarray-dependent data, GSE29384, GSE7181 and GSE23806 through searching GEO datasets (Figure 1B). As shown in Figure 1C, 327 genes were upregulated and 559 genes were downregulated, Scatter plot of gene expression in glioma compared with the control group. Then, gene ontology analysis (GO) was used to explore the roles of these differentially expressed lncRNAs. Results showed the majority of lncRNAs were assessed to be related to cancer progression (molecular function, cellular components and biological processes) (Figure 1D, E). Subsequently, GSEA results from microarray database showed that high lncRNA-PVT1 expression was associated with wnt pathway, cell adhesion and disease free survival of patients with glioma (Figure 1F, G). Therefore, we suggested that lncRNA-PVT1 might play critical roles in glioma progression.

**High lncRNA-PVT1 expression in glioma cells and tissues**

To enrich the dysregulated lncRNAs-mRNAs and their correlations, the tumor development data were collected from TCGA Pan-Cancer database. The results illustrated that the expression of lncRNA-PVT1 was pronouncedly increased in glioma tumor tissue compared to normal tissues. In most other solid tumors, such as breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma and cholangio carcinoma, lncRNA-PVT1 showed the opposite expression level (Figure 2A, B) (p < 0.001). Further, the expression level of lncRNA-PVT1 in glioma gradually increased with the increase of clinical stage, and the difference was significant (p < 0.05) (Figure 2C).

To assess the roles lncRNA-PVT1 in glioma, qRT-PCR showed that lncRNA-PVT1 was significantly upregulated in glioma tissue compared to adjacent non-tumor tissues (Figure 2D). High lncRNA-PVT1 expression was increased in glioma patients with advanced TNM stage and metastasis (Figure 2E, F). Furthermore, we analyzed the relationship between lncRNA-PVT1 expression and clinicopathologic features. Results showed that high lncRNA-PVT1 expression was associated with advanced tumor stage, metastasis, OS and DFS (Figure 2G, H). These data indicated that lncRNA-PVT1 might be involved in glioma metastasis.

To further determine the underlying mechanisms of lncRNA-PVT1 on glioma progression, loss-of-function assays were used. The expression of lncRNA-PVT1 was significantly reduced in U251 and U87 cells transfected with sh-lncRNA-PVT1 (Figure 3A-C). MTT assays showed that lncRNA-PVT1 suppression reduced the proliferation ability of U251
and U87 cells (Figure 3D-F). Human umbilical vein endothelia cells (2 × 10⁴ cells / well) were resuspended in the supernatant from sh-lncRNA-PVT1-U251 or sh-NC-U251 cells, and sh-lncRNA-PVT1-U87 or sh-NC-U87 cells. Then number of junctions and the total tubule length were chosen to assess the differences groups through ImageJ software. Next, the supernatants from sh-lncRNA-PVT1-U251 and sh-lncRNA-PVT1-U87 cells exhibited a strong negative effect on tubule formation of HUVECs, compared to control supernatants (p < 0.05) (Figure 3G-I). Transwell assays showed a similar result as tubule formation assays, sh-lncRNA-PVT1 significantly repressed the cell invasion of glioma cancer cells (Figure 3J-L).

Figure 1. Dysregulated expression profiles of lncRNAs in glioma. (A) Aberrantly expression of lncRNAs was evaluated in 3 pairs of glioma and adjacent normal tissues though lncRNA expression microarray. (B) lncRNA-PVT1 expression in microarray datasets GSE29384, GSE7181 and GSE23806. (C) Scatter plot of gene expression in glioma compared with the control group (x-axis). Up-regulated lncRNAs are shown in red while down-regulated lncRNAs are shown in green. (D, E) GO biological process classification for differently expressed lncRNAs. The upper graph was related to the up-regulated lncRNAs (D) while the lower graph was related to the down-regulated lncRNAs (E). (F, G) GSEA revealed that proliferation and metastasis related biological functions were enriched in response to high lncRNA-PVT1 expression based on the microarray data set.

http://www.jcancer.org
Identification of lncRNA-PVT1 target genes

To further explore whether lncRNA-PVT1 serve as an endogenous RNAs (ceRNA) to exerts its function in glioma cells, we first examined lncRNA-PVT1 expression in the cytoplasmic and nuclear fractions of glioma cells. The results indicated that lncRNA-PVT1 was in the cytoplasm, which is the pre-condition of acting as a ceRNA (Figure 4A). We found that miR-1207-3p ranked top among all potential targets by bioinformatics analysis (miRcode, Starbase, and LncBase Predicted), the secondary structure and possible binding sites was shown in Figure 4B. The results illustrated that the expression of miR-1207-3p was pronouncedly increased in TCGA Pan-Cancer database (Figure 4D). The dual-luciferase reporter assay showed that the luciferase activity of HEK293 cells transfected with lncRNA-PVT1-Wt could be reduced by miR-1207-3p mimics (Figure 4E). Kaplan-Meier analysis in the TCGA database with glioma revealed that high lncRNA-PVT1 expression level was significantly correlated with a reduction in OS and DFS (Figure 4F), which is consistent with the important role of lncRNA-PVT1 in the pathogenesis and the prognosis of glioma in our study.

lncRNA-PVT1 regulates the expression of HNF1B by competitive adsorption of miR-1207-3p

Next, we explored the functions of miR-1207-3p in glioma. We further predicted the targeting sites between miR-1207-3p and HNF1B and found that miR-1207-3p shared complementary binding sites with HNF1B at 3'-UTR (Figure 5A). To verify the predicted results, dual-luciferase reporter assay showed that miR-1207-3p mimics significantly reduced luciferase activities of HNF1B-Wt group (Figure 5B). In addition, miR-1207-3p mimics significantly decreased HNF1B mRNA expression, while miR-1207-3p inhibitors increased HNF1B

Figure 2. lncRNA-PVT1 was upregulated in glioma. (A, B) lncRNA-PVT1 expression in multiple solid tumors and normal tissues from TCGA Pan-Cancer dataset. (C) lncRNA-PVT1 expression in different TNM stage of glioma cases from TCGA dataset. (D) The lncRNA-PVT1 expression in glioma cases were determined by qRT-PCR assay. (E, F) High lncRNA-PVT1 expression was positively associated with advanced TNM stage and metastasis in patients with glioma. (G, H) The Kaplan-Meier curves introduced for survival analysis in glioma patients with high level and low level of lncRNA-PVT1. **p<0.01, ***p<0.001.
mRNA expression (Figure 5C). IHC results showed that both HNF1B protein expression was upregulated in glioma tissues and positively associated with advanced TNM stage (Figure 5D), which was further confirmed by TCGA database. Western blot results showed that overexpression of miR-1207-3p significantly down-regulated HNF1B compared with the control group, suggesting that HNF1B expression is inversely regulated by miR-1207-3p in glioma (Figure 5E, F). Those data indicated that HNF1B and foxm1 might play critical roles in glioma progression.

Figure 3. IncRNA-PVT1 promotes glioma the development of pro-metastatic phenotype in vitro. (A) IncRNA-PVT1 expression in glioma cell lines (H4, SHG-44, U87 and U251) and HEB was detected by qRT-PCR assay. (B, C) Knockdown of IncRNA-PVT1 by shRNA in U87 and U251 cells. (D-F) MTT assay was performed to assess the function of IncRNA-PVT1 in glioma cells proliferation. (G-I) The supernatants from sh-lncRNA-PVT1 cells exhibited a strong negative effect on tubule formation of HUVECs, compared to control supernatants in U87 and U251 cells. (J-L) Knockdown of IncRNA-PVT1 in U251 and U87 cells significantly inhibited cell invasion. We selected the 1# and 2# sh-plasmids with high interference efficiency for testing. *p<0.05.
lncRNA-PVT1/miR-1207-3p/HNF1B axis promoted glioma progression

To determine whether the effects of lncRNA-PVT1 in glioma cells metastasis were dependent on miR-1207-3p/HNF1B axis, we further tested the roles of lncRNA-PVT1/miR-1207-3p/HNF1B axis in glioma progression. Furthermore, we examined the effects of lncRNA-PVT1 in xenograft mouse model. Results revealed that lncRNA-PVT1 inhibition also significantly reduced tumor growth in vivo (Figure 6A-C). Overall, these results indicated that lncRNA-PVT1 silencing significantly reduced the proliferation and invasion ability of glioma cells in vitro and reduced tumor growth in vivo. EMT processes play critical roles in tumor metastasis. In the present study, western blot showed that lncRNA-PVT1 inhibition significantly reduced EMT related gene expression (Vimentin and N-cadherin) and MAPK pathway related gene expression (foxm1, VEGFA and PKP4) expression. And the effects of lncRNA-PVT1 inhibition on MAPK signaling pathway and EMT processes could be restored by miR-1207-3p shRNAs (Figure 6F). Thus, our data suggested that lncRNA-PVT1 promoted the proliferation and metastasis of glioma by regulating miR-1207-3p/HNF1B/MAPK pathway (Figure 6D-E).
Figure 5. HNF1B is the direct target gene of miR-1207-3p and associated with poor prognosis of glioma. (A) The predicted complementary binding sites between miR-1207-3p and HNF1B. (B) Dual-luciferase assay showed miR-1207-3p mimics reduced the luciferase activity of HNF1B-Wt. (C) miR-1207-3p mimics reduced HNF1B expression in glioma cells, while miR-1207-3p inhibitors increased HNF1B mRNA expression. (D) IHC assays showed HNF1B expression was upregulated and associated advanced TNM stage in patients with glioma. (E, F) Western blot results showed overexpression of miR-489 significantly down-regulated HNF1B in U87 and U251 cells. *p<0.05.

Figure 6. lncRNA-PVT1 inhibition reduced tumor growth in vivo, and lncRNA-PVT1/miR-1207-3p/HNF1B axis promoted glioma metastasis. (A) Representative images of tumors in xenograft mouse model. (B) The relative weights of xenograft tumors. (C) The growth curves of xenograft tumors. (D, E) HALLMARK and KEGG Pathway Enrichment in glioma from microarray datasets. The datasets were analyzed using the Hallmark gene signature collection. Hallmark_EMT was identified as the pathway with the top two-highest association. (F) The expressions of HNF1B, EMT-related markers and VEGF-related molecules were determined using western blot. Proteins were isolated from cells transfected as indicated. *p<0.05, **p<0.01, ***p<0.001.
Discussion

At present, only a few functional mechanisms of lncRNAs have been well characterized, and some recent insights into lncRNAs identified in other diseases and cancers, such as molecules encoding tumor-related micropeptides, changes in the activities or conformation of proteins and the regulation of tumor microenvironment homeostasis, have not yet been clearly demonstrated in glioma pathogenesis [33]. The majority of studies of glioma-associated lncRNAs are typically focused on ceRNA regulatory networks [34]. Thus, there is an urgent need to elucidate the detailed mechanisms of the roles of lncRNAs in glioma.

Glioma displays complex etiology involving multiple risk factors, such as environmental exposure, inherited genetic alterations, and multiple epigenetic modifications based on global molecular biomarkers, including mRNAs and lncRNAs [35, 36]. Although surgical resection is the best chance for a possible cure, the prognosis of glioma remains poor [37]. Therefore, it is highly desirable to identify and characterize genes that play important roles in glioma pathogenesis. Among the critical molecules involved in the glioma progression, lncRNAs gradually become an attractive therapeutic target for cancers [38]. For example, Yang et al. found that lncRNA-BANCR promoted non-small-cell lung cancer cells growth and metastasis via affecting EMT processes [39]. Fu et al. found that lncRNA-HOTTIP modulated cancer stem cell properties through regulating HMGA1 in human gastric cancer [40]. Jin et al. suggested that lncRNA-HOTTIP enhances osteogenic differentiation via interaction with WDR5 and up-regulation of β-catenin gene expression, therefore activating Wnt/β-catenin signalling pathway [41]. Additionally, whether lncRNA expression in glioma is dysregulated and abnormal remains elusive, and the underlying mechanisms are still unknown.

LncRNA-PVT1 is reported to be involved in tumorigenesis and progression of many malignancies,
including cervical cancer, nonsmall cell lung cancer, pancreatic cancer, and so forth [42]. In the recent years, some emerging evidence has suggested that silencing PVT1 could inhibit malignant biological behaviors of glioma cells [43]. For instance, Xue et al. unraveled that knockdown of PVT1 weakened the malignant behaviors of glioma cells via the inhibition of cell motility and invasiveness [44]. Wang et al. also substantiated that downregulation of PVT1 expression resulted in decreased cell viability and mobility and increased apoptosis [45]. In addition, lncRNAs can act as competing endogenous RNA sponges for miRNAs to regulate the degradation of miRNA targets, thereby influencing post-transcriptional regulation. In our study, we revealed that IncRNA-PVT1 was obviously increased in glioma tissues as well as in glioma cell lines. High IncRNA-PVT1 expression was positively associated with advanced TNM stage, metastasis, and poor prognosis in patients with glioma. In addition, loss-of-function assays demonstrated that IncRNA-PVT1 inhibition suppressed the proliferation and invasion in glioma cells in vitro and reduced tumor growth in vivo. Then the regulatory relationship between IncRNA-PVT1 and miR-1207-3p was validated through bioinformatics analysis, luciferase reporter assay as well as FISH assay. The present study further confirmed that transcriptional activation of IncRNA-PVT1 contributed to oncogenesis, whereas knockdown of IncRNA-PVT1 impaired oncogenic function of HNF1B in glioma cells. These data suggested that IncRNA-PVT1 could play critical roles in glioma tumorigenesis.

HNF1B could play critical functions in proliferation, metastasis, apoptosis, and linked to EMT pathway in several cancers [46-49]. In our study, by bioinformatic prediction and experimental verification, we showed that HNF1B could act as a direct target of miR-1207-3p in glioma. Furthermore, we showed that the anti-metastatic roles of IncRNA-PVT1 inhibition on glioma cells invasion could be abolished by co-transfected with miR-1207-3p inhibitors (or pcDNA3.1_HNF1B plasmid). In addition, western blot revealed that IncRNA-PVT1 inhibition significantly reduced the expression of EMT pathway related genes. And the effects of IncRNA-PVT1 inhibition on EMT pathway could be restored by co-transfected with miR-1207-3p inhibitors. Therefore, these findings suggested that IncRNA-PVT1 promoted the proliferation and invasion in glioma via regulating miR-1207-3p-mediated HNF1B/EMT pathway.

In summary, our study identified the interaction between IncRNA-PVT1, miR-1207-3p and HNF1B in glioma (Figure 7). In the present study, miR-1207-3p was predicted as the target of IncRNA-PVT1. Dual-luciferase reporter assay confirmed the correlation between IncRNA-PVT1 and miR-1207-3p. Furthermore, transwell invasion assay further revealed that IncRNA-PVT1 promoted glioma cells invasion by downregulating miR-1207-3p expression. Overall, we suggested that IncRNA-PVT1 could act as a sponge for miR-1207-3p in glioma. And the IncRNA-PVT1/miR-1207-3p/HNF1B/MAPK axis might provide a new potential therapeutic target for treatment of glioma.

Acknowledgments

We are appreciating to every author for their assistance with the experiments and constructive comments on the manuscript.

Ethics approval and consent to participate

Ethical approval was given by the Ethics Committee of Fudan University.

Availability of data and materials

The dataset supporting the conclusions of this article is included within the article.

Author Contributions

Yongyan Bi, Jie Ji, Youxin Zhou conceived and designed the study. Yongyan Bi performed all the in vitro experiments. Yongyan Bi, Jie Ji, Youxin Zhou provided support with experimental techniques. Yongyan Bi, Jie Ji, Youxin Zhou collected clinical data. Yongyan Bi analyzed the data and prepared the manuscript. Yongyan Bi, Jie Ji, Youxin Zhou reviewed and revised the manuscript. Yongyan Bi, Jie Ji, Youxin Zhou provided material support and supervised all experiments. All authors read and approved the final manuscript.

Funding

This study was supported by Minhang District Natural Science Foundation Project (No. 2020MHZ084) and Minhang district High-level Specialized Backbone Doctor Doctor Training plan.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434-452.
2. Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer. 2020 Jan;20(1):57-70.
3. Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics. 2017 Apr;14(2):284-297.
4. Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol. 2018 Aug;51:50-58.
5. Hervey-Jumper SL, Berger MS. Insular glioma surgery: an evolution of thought and practice. J Neurosurg. 2019 Jan;130(1):9-16.

6. Puvvalu PK. lncRNAs Regulatory Networks in Cellular Senescence. Int J Mol Sci. 2019 May 28;20(11):2615.

7. Cripe TP. lncRNAs Coming of Age. Circ Res. 2018 Aug 17;123(5):535-537.

8. Wu, Du Y. lncRNAs: From Basic Research to Medical Application. Int J Biol Sci. 2017 Feb 23;13(3):295-307.

9. Meng Y, Qiu S, Sun L, Zuo J. Knockdown of exosome-mediated Inc-PVT1 alleviates lipopolysaccharide-induced osteoarthritis progression by mediating the HMGB1/TLR4/NF-κB pathway via miR-93-5p. Mol Med Rep. 2020 Dec;22(6):5313-5325.

10. Qiu C, Li S, Sun D, Yang S. IncPVT1 accelerates progression of non-small cell lung cancer via targeting miRNA-226b/EIF2H2 regulatory loop. Oncol Lett. 2020 Feb;19(12):1267-1272.

11. Chang QQ, Chen CY, Chen Z, Chang S. lncRNA PVT1 promotes proliferation and invasion through enhancing Smad3 expression by sponging miR-140-5p in cervical cancer. Radiol Oncol. 2019 Oct 18;53(4):443-452.

12. Pan X, Cheng R, Zhu X, Cai F, Zheng G, Li J, Gao C. Prognostic Significance and Diagnostic Value of Overexpressed IncRNA PVT1 in Colorectal Cancer. Clin Lab. 2019 Dec 16;5(12).

13. Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 2015 Jul 3;462(3):227-32.

14. Lu D, Luo P, Wang Q, Ye Y, Wang B. IncRNA PVT1 in cancer: A review and meta-analysis. Chin Clin Acta. 2017 Nov;74:471-1.

15. Tang J, Li Y, Sang Y, Yu B, Lv D, Zhang W, Feng H. lncRNA PVT1 regulates triple-negative breast cancer through KLRF/β-catenin signaling. Oncogene. 2018 Aug;37(34):4723-4734.

16. Yoshida K, Toden S, Ravindranathan P, Han H, Goel A. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the IncRNA PVT1 expression. Carcinogenesis. 2017 Oct;138(3):1036-1046.

17. Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q, Tan C, Ni SJ, Dong L, Yang Y, Lin W, Xu Q, Huang D, Huang Z, Ma Y, Zhang W, Sheng W, Du X. A Positive Feedback Loop of IncRNA-PVT1 and FOXMI1 Facilitates Gastric Cancer Growth and Invasion. Clin Cancer Res. 2017 Apr 15;23(8):2071-2080.

18. Wang Y, Chen W, Lian J, Zhang H, Yu B, Zhang M, Wei F, Wu J, Jiang J, Jia Y, Mo F, Zhang S, Liang X, Mou X, Tang J. The IncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1α. Cell Death Differ. 2020 Feb;27(2):695-710.

19. Han Y, Li Z, He F, Yan J, Ma C, Zheng X, Zhang J, Zhang D, Meng C, Zhang Z, Ji X. Knockdown of IncRNA PVT1 Inhibits Gloma Proliferation and EMT by Regulating miR-24-2. J Biol Chem. 2020 Jun 23;295(25):22420-22432.

20. Zhang Y, Yang G, Luo Y. Long non-coding RNA PVT1 promotes glioma cell proliferation and invasion by targeting miR-200a. Exp Ther Med. 2020 May;20;12:11325-11338.

21. Shao Y, Chen HT, Ma QR, Zhang YW, He YQ, Liu J. Long non-coding RNA PVT1 regulates glioma proliferation, invasion, and aerobic glycolysis via miR-140-5p. Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):274-283.

22. Xue W, Chen J, Liu X, Yang G, Luo Y, Hu Y, Yang Z, Hu Y, Liu J, He Y. A IncRNA HOTTIP Promotes Cisplatin Resistance in Gastric Cancer Cells. Mol Cancer. 2019 Jan;18;50:205-216.

23. Shao Y, Chen HT, Ma QR, Zhang YW, He YQ, Liu J. Long non-coding RNA PVT1 regulates glioma proliferation, invasion, and aerobic glycolysis via miR-140-5p. Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):274-283.

24. Xue W, Chen J, Liu X, Yang G, Zheng J, Guo L, Liu J, He Y, Liu J, Ma W, Li J, Zuo J, Xue Y. PVT1 regulates the malignant behaviors of human glioma cells by targeting miR-190a-5p and miR-488-3p. Biochim Biophys Acta. 2021 May;1880(1):128-134.

25. Shao Y, Chen HT, Ma QR, Zhang YW, He YQ, Liu J. Long non-coding RNA PVT1 regulates glioma proliferation, invasion, and aerobic glycolysis via miR-140-5p. Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):274-283.
epigenetic/bookmarking function of HNF1B. Nucleic Acids Res. 2016 Sep 30;44(17):8097-111.